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Abstract: PIKfyve is an evolutionarily conserved lipid and protein kinase enzyme that has pleiotropic cellular functions. The aim of the
present study was to investigate the effects of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) inhibitor, YM201636, on nonsmall
cell lung cancer (NSCLC) cells growth, tumorigenicity, and claudin (CLDN) expressions. Three NSCLC cell lines (Calu-1, H1299 and
HCC827) were used to compare the effects of YM201636. Cytotoxic effects of YM201636 were analysed using XTT assay. Malignancy
potential of cells assesses with wound healing and soft agar colony-forming assays. mRNA and protein expressions of claudins were
analysed by qRT-PCR and immunofluorescence staining. Our results revealed that YM201636 inhibited the proliferation and malignancy
potential of Calu-1, H1299, and HCC827 cells in a dose-dependent manner. After YM201636 treatment CLDN1, -3 and -5 expressions
increased significantly in HCC827 cells. CLDN3 and -5 expressions also significantly increased in Calu1 cell line. YM201636 treatment
significantly reduced the CLDN1 and increased the CLDN5 expression in H1299 cells. Immunofluorescence staining of CLDN1, -3
and -5 proteins showed a significant increase after YM201636 treatment. Besides, YM201636 induced EGFR mRNA expression in all
NSCLC cell lines. Our results have shown that YM201636 inhibits tumorigenicity of NSCLC cells. Furthermore, estimated glomerular
filtration rate (EGFR) pathway is important signalling involved in the regulation of claudins. Understanding the mechanisms of PIKfyve
inhibitors may improve cancer treatment particularly for EGFR overactivated NSCLC.
Key words: Claudin, epidermal growth factor receptor, nonsmall cell lung cancer, PIKfyve, YM201636

1. Introduction
Lung cancer is one of the most common cancer type that
is expected to be diagnosed in men and women in 2020
(Siegel, et al. 2020). Nonsmall cell lung cancer (NSCLC)
accounts for 85% of all lung cancer cases. Delayed first
diagnosis, chemotherapy resistance and aggressiveness of
the tumour cells are still major obstacles in the lung cancer
treatment, and novel therapeutic agents are urgently
needed.
PIKfyve (phosphoinositide kinase, FYVE-type
zinc finger containing) is an evolutionarily conserved
lipid and protein kinase that has pleiotropic cellular
functions (Shisheva, 2008). Phosphorylation of the
phosphatidylinositol-3-phosphate (PI3P) by PIKfyve
generates
phosphatidylinositol
3,5-bisphosphate
[PtdIns(3,5)P2] or phosphatidylinositol 5-phosphate
(PtdIns5P) (Shisheva, 2001). These two phosphoinositide
(PI) derivatives have been proposed to be involved in:
intracellular membrane trafficking pathways (Ikonomov et

al., 2006; Sbrissa et al., 2007), translocation of the glucose
transporter GLUT4 after insulin stimulation (Sbrissa et al.,
2004), regulation of synapse strength (McCartney et al.,
2014), remodelling the actin cytoskeleton (Ikonomov et
al., 2018), and epidermal growth factor receptor (EGFR)
signalling (Kim et al., 2007). Besides the physiological
roles, PIKfyve has been associated with oncogenesis and
cancer cell migration (Oppelt et al., 2014; Oppelt et al.,
2013). Therefore, inhibition of PIKfyve activity has been
started to explore as an anticancer therapy.
YM201636 compound was discovered as a selective
small-molecule inhibitor of PIKfyve leading to the
accumulation of a late endosomal compartment and
blockade of retroviral exit (Jefferies et al., 2008). YM201636 mediated PIKfyve inhibition significantly reduced
the survival of primary mouse hippocampal neurons
and promoted vacuolation of endolysosomal membranes
followed by apoptosis-independent cell death (Martin
et al., 2013). It was demonstrated that YM201636 blocks
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the continuous recycling of the tight junction proteins
claudin-1 (CLDN1) and claudin-2 (CLDN2) (Dukes
et al., 2012). Tight junctions (TJs) are intramembrane
multiprotein complexes that provide apical intercellular
connections between adjacent cells in both epithelial and
endothelial monolayers (Shin et al., 2006). In particular,
barrier functions of TJs are important for lung defence; so
they are considered as a part of the innate immune system
(Soini, 2011).
Claudins are structural molecules of TJs and responsible
for the regulation of the paracellular permeability of cells
(Salvador et al., 2016). Alteration of claudin expressions
in lung tumours have been reported by several studies;
however, the effects of PIKfyve inhibitor YM201636 on
NSCLC cells have not been investigated. Thus, we aimed
to investigate the effects of YM201636 on NSCLC cells
proliferation, malignancy potential, and expressions of
CLDN1, -3 and -5, which are “pore-sealing” claudins, and
increased expression of them leads to increased tightness
of epithelial monolayer and transepithelial electrical
resistance and decreases permeability (Krause et al., 2009).
2. Materials and methods
2.1. Cells and reagents
To compare the effects of YM201636, we used three
NSCLC cell lines (Calu-1, H1299, and HCC827) with
different genotypic backgrounds. Calu-1 and H1299 are
carcinoma cell lines carrying homozygous TP53 deletion
and lack of expression of p53 protein. HCC827 cell line
possesses EGFR mutation (exon19del E746-A750), which
leads to constitutively activated EGFR.
All cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, USA). Cell culture
media and supplements were obtained from Biological
Industries (Bio Ind. Kibbutz Beit Haemek, Israel). Calu1 cells were cultured in DMEM (Dulbecco’s modified
Eagle’s medium); HCC827 and H1299 cells were cultured
in RPMI-1640 medium in a humidified 37 °C incubator
with 5% CO2. Both medias were supplemented with 10%
FBS (fetal bovine serum), 1% L-glutamine, and penicillinstreptomycin.
YM201636 was obtained from Cayman Chemical
(#13576) and dissolved in DMSO (final concentration 10
mM). For mRNA expression analysis primer, probe and
enzymes were purchased from Roche Applied Science
(Mannheim, Germany).
2.2. Cytotoxicity assay
Calu-1, H1299, and HCC827 cells were seeded into 96well plates at a density of 2×104 per well. The next day, cells
were treated with increasing concentrations of YM201636
(1, 2.5, 5, 7.5, 10, 12.5, 15, and 20 µM). Control groups were
treated with the DMSO according to the concentration in
the YM201636. After 24, 48, and 72 h, 50 µL of XTT solution

(Bio Ind. Kibbutz Beit Haemek, Israel) was added to each
well, and the plate was incubated for 4 h. The absorbance
of each well was measured spectrophotometrically at
450 nm with an ELISA reader (Thermo Fisher Scientific,
Massachusetts, USA). All concentrations were triplicated
and experiments repeated at least 3 times. The growth
inhibition percentage was calculated as follows:
Growth inhibition % = (ODcontrol - ODYM201636)/ODcontrol ×
100
2.3. Quantitative reverse-transcription polymerase chain
reaction (qRT-PCR)
mRNA expression patterns of CLDN-1, -3, -5 and EGFR
were assessed by quantitative real-time PCR. qRT-PCR
analysis was performed on the LightCycler™ 2.0 instrument
(Roche Applied Science, Penzberg, Germany). Relative
quantification of each sample with glyceraldehyde-3phosphate dehydrogenase (GAPDH) was achieved by
using different standards included in each run.
2.4. Immunofluorescence staining
Calu-1, H1299, and HCC827 cells were cultured on 15
mm cover glasses (5x105 cells/mL). After 24 h incubation,
cells were fixed in 4% paraformaldehyde (Sigma, #P-6148)
for 30 min and treated with 0.25% Triton X100 (Bio Basic
Canada Inc. C34H62O11) for 15 min and blocked with
1% bovine serum albumin (BSA, Chem Cruz, #sc2323) in
1× phosphate-buffered saline (PBS). Primary antibodies,
claudin-1 (Proteintech, #22952-1-AP), claudin-3 (Santa
Cruz, #sc271631), and claudin-5 (Proteintech, #22023-1AP) were diluted 1/100 and incubated at 4 oC overnight.
Secondary antibody (Invitrogen Alexa Fluor 488,
#A11034 anti-rabbit) was diluted 1/200 and incubated for
1 h. Samples were mounted with Fluoroshield Mounting
Medium with DAPI (Abcam, #ab104139) and observed
by the appropriate fluorescent filter by Olympus CellSens
Entry.
2.5. Wound healing assay
Wound healing assay was used to measure the migration
of NSCLC cells. For this purpose, Calu-1, H1299, and
HCC827 cells were seeded in six-well plates at a density of
5x105 cells in 2 mL medium per well. Twenty-four-hours
later, the cell monolayer was scratched with a sterile 100 μL
pipette tip, then washed twice with PBS to remove debris
which was followed by the addition of fresh medium that
contained IC50 concentrations of YM201636. After 24 and
48 h, the gap distance was photographed using an inverted
light microscope.
2.6. Soft agar colony-forming assay
Anchorage-independent growth assay was performed
using the Cytoselect 96-well Cell Transformation Assay Kit
(Cell Biolabs, # CBA-130). Calu-1, H1299, and HCC827
cells (3 × 104) with various concentrations of YM201636
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were seeded onto 96-well plates. After 7 days, colonies
were counted and photographed.
2.7. Statistical analysis
IC50 concentrations of YM201636 were calculated with the
GraphPad Prism. Statistical analyses were performed using
IBM SPSS Statistics version 21 (IBM Corp., Armonk, NY,
USA). One‑way analysis of variance (ANOVA) followed
by Bonferroni or Dunnett’s T3 test was used for post hoc
multiple comparisons. A two‑tailed unpaired t‑test was
used for the comparison of the mean values between two
groups. P < 0.05 was considered as statistically significant.
3. Results
3.1. Cytotoxic effects of YM201636 on NSCLC cell lines
To analyse the cytotoxic effects, NSCLC cells were
treated with different concentrations of YM201636. After
incubation for 24, 48, and 72 h, the viability was assessed
using XTT cytotoxicity assay. Our results indicate that
YM201636 decreased the viability of all cell lines (Figure
1). However, Calu1 and HCC827 cells were more sensitive
to YM201636 with the 15.03 and 11.07 μM IC50 at the 72

h, respectively. Whereas H1299 cell line had 74.95 μM IC50
level for YM201636.
3.2. YM201636 induces Claudin-1, -3 and-5 expressions
Previous studies have demonstrated that inhibition of
PIKfyve via YM201636 treatment blocks the endocytic
recycling of claudins (Dukes et al., 2012). We aimed to
evaluate the effects of YM201636 on claudin-1, -3, and
-5 expressions at the transcriptional level. Our qRT-PCR
results showed that CLDN1 expression was significantly
increased in HCC827 cells after 20 µM YM201636
treatment (Figure 2). However, CLDN1 expression tended
to decrease with dose dependent manner in H1299 cells.
On the other hand, CLDN3 and CLDN5 expressions
were increased in all cell lines after YM201636 treatment
(Figures 3 and 4). Except the CLDN3 expression in H1299,
all increments were statistically significant for CLDN3
and -5. Furthermore, immunofluorescence staining of
claudin-1, 3, and 5 proteins showed a significant increase
after YM201636 treatment (Figure 2a, 3a and 4a).
Hou et al. demonstrated that YM201636 suppressed the
growth of liver cancer cells via the induction of autophagy
upon EGFR overexpression (Hou et al., 2019). Therefore,

Figure 1. Effects of YM201636 on NSCLC cells proliferation. XTT assay was performed using A-) Calu-1, B-) H1299, and C-) HCC827
cell lines. D-) After 24, 48, and 72h exposure IC50 levels were calculated using GraphPad Prism 5.
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Figure 2. Effects of YM201636 on Claudin-1 expression. A-) mRNA analysis of CLDN1. Cells were treated with different concentrations
of YM201636 (Calu-1: 10, 20, and 30 μM; H1299: 25, 50, and 75 μM; HCC827: 5, 10, and 20 μM) for 48 h. UT: Untreated cells. *P =
0.001, UT vs 20 µM. B-) Immunofluorescence staining of CLDN1 protein in NSCLC cells treated with YM201636 at IC50 doses. ×40
magnification.

we analysed the EGFR expression after YM201636
treatment. Our results showed that EGFR expression was
increased in all cell lines after YM201636 treatment and
increment was significant for Calu1 and HCC827 cells
(Figure 5).
3.3. Colony formation and cell migration after YM201636
treatment
To study the effects of YM201636 on malignity potential
of NSCLC cells, we analysed the anchorage-independent
growth and cell migration.
For the anchorage-independent growth, cells were
treated with 3 different concentrations of YM201636. As
shown in the figure 6a - b, YM201636 treated Calu1 cells
displayed significant decrease in the number of anchoragedependent colonies at all doses (P < 0.0001). However,
YM201636 treatment inhibited the colony formation only
at the highest dose for H1299 (P = 0.005) and HCC827 (P
= 0.006) cells.

The capacity of cell migration was evaluated by
wound healing assay as shown in Figures 6c and 6d.
The monitored wound closure showed that YM201636
treatment significantly inhibited migration at Calu1 (P =
0.035), H1299 (P < 0.0001) and HCC827 (P = 0.0001) cells
after 48h incubation. For the 24h, significant inhibition
was detected at the H1299 (P < 0.0001) and HCC827 (P
= 0.002) cells.
These results demonstrated that exposure to the
YM201636 significantly decreased the malignity potential
of cells; therefore, PIKfyve kinase inhibition could be a
target in NSCLC.
4. Discussion
In this study, we have used the PIKfyve inhibitor YM201636
to investigate the effects on proliferation, malignity
potential, and claudin expressions in the NSCLC cell
lines. Cytotoxicity assays show that YM201636 decreased
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Figure 3. Effects of YM201636 on Claudin-3 expression. A-) mRNA expression and B-) immunofluorescence staining of CLDN3 in
NSCLC cells after YM201636 treatment. UT: Untreated cells, *P = 0.007, UT vs. 30µM, ×40 magnification.

the viability of all cell lines and Calu1 and HCC827 cells
were more sensitive to YM201636. Different sensitivity to
YM201636 may be due to genetic background of cells, and
we speculated that EGFR overactivated cells were more
sensitive to PIKfyve inhibition.
It was demonstrated that cytotoxicity of PIKfyve
inhibitors requires growth factor/Akt suppression and
excessive cytoplasmic vacuolation (Ikonomov et al.,
2018). PIKfyve inhibitors disrupted lysosomal function,
autophagic flux, and the high basal necessity of autophagy
in plasma cells and multiple myeloma cells (de Campos et
al., 2020). Therefore, inhibition of PIKfyve was suggested
as a novel target for multiple myeloma. In addition, Hou
et al. reported that YM201636 possess an inhibitory effect
on tumour cell growth via the induction of autophagy in
the hepatoma cell lines and in vivo models without any
adverse effects (Hou et al., 2019). Our results showed the
cytotoxic effects of YM201636 on the NSCLC cell lines and
supported previous studies.
YM201636 inhibited the endocytic recycling of
claudin-1 and -2, leading the accumulation of them
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intracellularly and delays epithelial barrier formation
(Dukes et al., 2012). However, claudin-4 showed negligible
endocytosis, and no detectable intracellular accumulation
occurred following treatment with YM201636, suggesting
that not all claudins show the same rate of endocytic
trafficking.
Claudins are structural proteins of TJs and localisation
and expression of them regulate several cell functions
(Martin and Jiang 2009). The distinct claudin expression
profile was reported within the histologic subtypes of
NSCLC (Moldvay et al., 2007). Lung adenocarcinoma
patients with positive CLDN1 expression had poorer
prognosis than negatives, and combination of CLDN1/
Ras/EGFR was reported as a valuable independent
prognostic factor (Sun et al., 2016). On the contrary,
CLDN1 positivity predicted a better survival in adeno and
squamous cell carcinoma (Merikallio et al., 2011; Moldvay
et al., 2017). CLDN3 expression was significantly increased
in lung adenocarcinoma tissues and it was associated with
cancer progression and poor survival (Zhang et al., 2017).
CLDN3 was reported as a positive regulator of cancer
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Figure 4. Effects of YM201636 on Claudin-5 expression. A-) mRNA expression and B-) immunofluorescence staining of CLDN5 in
NSCLC cells after YM201636 treatment. UT: Untreated cells, *P = 0.015, ×40 magnification.

Figure 5. YM201636 induced EGFR mRNA expression in NSCLC cells. A-) Calu-1, B-) H1299, and C-) HCC827 cell line.
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Figure 6. Effects of YM201636 on the tumorigenicity of NSCLC cells. A-) Colony-formation assay. Cells were treated with different
concentrations of YM201636 (Calu-1: 10, 20, and 30 μM; H1299: 25, 50, and 75 μM; HCC827: 5, 10, and 20 μM). Colonies were counted
and photographed on the 7th day. B-) Quantification of the number of colonies normalized to control cells. (*P = 0.0002, **P < 0.0001,
***P = 0.005, ****P = 0.006, Dunnett’s test) C-) Wound healing assay of NSCLC cells treated with YM201636 at the IC50 doses. Images
were taken at 0, 24, and 48h. D-) Wound healing images were analysed using the Image J software to quantification of the areas. The
graph shows the average values and the standard error of three experiments. **P < 0.0001.
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stemness in nonsquamous NSCLC and its depletion
decreased the formation rates of spheres and tumours and
increased cisplatin sensitivity (Ma et al., 2019). In brief,
lung tumours with different histological types vary in
their claudin expression showing up or downregulation of
different claudins. It may not be sufficient to evaluate only
claudin’s expression to predict cancer progression.
Since previous studies showed that YM201636 inhibited
the endocytic recycling of claudins (Dukes et al., 2012),
we evaluated the claudin expressions after YM201636
exposure. Our results showed that CLDN1 expression
was significantly increased in HCC827 cells; CLDN3 and
CLDN5 were significantly increased in Calu1 and HCC827
cells after YM201636 treatment. These results show that
YM201636 affects the expression of claudins differently for
each cell lines. YM201636 treatment induced all claudins
(CLDN-1, -2, and -3) in EGFR mutant HCC827 cell line,
which was the most sensitive to YM201636. Interestingly,
YM201636 treatment reduced CLDN1, increased CLDN5
but did not change CLDN3 and EGFR expressions in H1299
cells, which is the less sensitive cell line to YM201636.
EGFR might be the key point for the regulation of
claudin transcription. It was reported that EGF and its
downstream signalling pathway MEK/ERK or PI3K/
AKT mediated the upregulation of CLDN3 expression
and maintain the basic level of claudins (Zhang et al.,
2017). Furthermore, YM201636-induced autophagy is
dependent upon EGFR overexpression (Hou et al., 2019).
Our study is consistent with previous results in terms of
YM201636 induced EGFR. Promoter regions of CLDN1
and CLDN3 contain Sp-1 transcription factor binding
site, which is crucial for their activation (Khan and Asif
2015). It was reported that EGFR signalling enhances
IRES-mediated translation of Sp1 during tumorigenesis,
and Sp1 accumulates in cancer cells (Hung et al., 2014).
This explains the increase of claudins particularly in EGFR
overactivated HCC827 cell line. Likewise, YM201636induced autophagy was associated with the presence
of EGFR (Hou et al., 2019). In this case, YM201636
induced EGFR protein was in an inactive form and it was
demonstrated that inactive EGFR complexes could initiate
autophagy (Hou et al., 2019; Tan et al., 2015).

EGFR activation significantly inhibited CLDN2
expression while increased CLDN1, -3, and -4 expression
in MDCK cells (Singh and Harris, 2004). In addition, EGFinduced alterations in claudin expressions significantly
amplified transepithelial resistance, which is a functional
biomarker for TJs. EGFR inhibition is a common targeted
therapy for EGFR over expressing tumours. It was reported
that EGFR inhibitor gefitinib induces barrier function in
human epidermal keratinocytes via the modulation of the
expression of claudins (Fang et al., 2019). EGFR-PKCCLDN1 pathway suggested as a tumorigenic pathway in
colon cancer cells (Kim et al., 2020). These results clearly
show that EGFR can both up- and downregulate claudin
expressions and effect TJs functions. However, further
studies are needed to find out the therapeutic potential of
EGFR-tight junction connection.
There are some limitations of our study; 26 claudins
are known to be expressed by humans, but we could not
analyse all of them (Soini, 2011). Also, we cannot analyse
autophagy markers and downstream proteins of the
EGFR pathway. We are planning to investigate detailed
mechanisms with further studies.
Overall, we have indicated that inhibition of PIKfyve
using YM201636 resulted in an inhibitory effect on NSCLC
cells growth and tumorigenicity. Furthermore, EGFR
pathway is an important signalling cascade involved in the
regulation of claudins. In conclusion, understanding the
mechanisms of PIKfyve inhibitors may provide beneficial
pharmacological combinations for improved efficacy
particularly in the treatment of EGFR overactivated
NSCLC.
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